Company registration number 12867402 (England and Wales)
ULTRAMEDIC GROUP LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
PAGES FOR FILING WITH REGISTRAR
ULTRAMEDIC GROUP LIMITED
BALANCE SHEET
AS AT 31 AUGUST 2025
31 August 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Investments
3
2,764,585
2,764,585
Current assets
Debtors
4
202,984
548,147
Cash at bank and in hand
535,488
302,234
738,472
850,381
Creditors: amounts falling due within one year
5
(42)
(110,882)
Net current assets
738,430
739,499
Net assets
3,503,015
3,504,084
Capital and reserves
Called up share capital
6
9,064
10,300
Profit and loss reserves
3,493,951
3,493,784
Total equity
3,503,015
3,504,084

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 27 May 2026 and are signed on its behalf by:
P Johnson
Director
Company registration number 12867402 (England and Wales)
ULTRAMEDIC GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
- 2 -
1
Accounting policies
Company information

Ultramedic Group Limited is a private company, limited by shares and incorporated in England and Wales. The registered office is Unit 4h, Wavertree Boulevard South, Liverpool, L7 9PF.

 

The principal activity of the company continued to be that of a holding company.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

1.2
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.3
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

ULTRAMEDIC GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 3 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.5
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

ULTRAMEDIC GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
2
3
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
2,764,585
2,764,585
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
172,671
548,147
Other debtors
30,313
-
0
202,984
548,147
ULTRAMEDIC GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 5 -
5
Creditors: amounts falling due within one year
2025
2024
£
£
Other borrowings
-
0
109,243
Corporation tax
42
-
0
Accruals and deferred income
-
0
1,639
42
110,882

Within other borrowings is an amount of £Nil (2024: £106,770) consisting of fixed rate secured loan notes. The loan notes are secured by a fixed and floating charge in respect of all of the assets of the group.

6
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A Shares of £1 each
9,064
9,064
9,064
9,064
Ordinary B Shares of £1 each
0
1,236
-
0
1,236
9,064
10,300
9,064
10,300

During the year, the company purchased and subsequently cancelled 1,236 Ordinary B shares. Details can be found at Companies House.

7
Related party transactions

Loan notes

 

In the 2021 period, a director received loan notes totalling £1,386,956 in return for shares held in an acquired subsidiary. The loan notes are repayable on an annual basis with a fixed rate of interest of 3%. Accrued interest is payable on an annual basis in arrears and principal is repayable annually with reference to 60% of the annual distributable profits of the Group.

 

During the year, the company made an annual payment of of £109,243 (2024: £452,970) and an interest payment of £1,639 (2024: £8,894) to the director in respect of the loan notes. As at the year end, the company owed the director £Nil (2024: £109,243) and accrued interest of £Nil (2024: £1,639).

 

 

2025-08-312024-09-01falsefalsefalse28 May 2026CCH SoftwareCCH Accounts Production 2026.100The principal activity of the company continued to be that of a holding company.P JohnsonV Mansley128674022024-09-012025-08-31128674022025-08-31128674022024-08-3112867402core:CurrentFinancialInstrumentscore:WithinOneYear2025-08-3112867402core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3112867402core:WithinOneYear2025-08-3112867402core:WithinOneYear2024-08-3112867402core:ShareCapital2025-08-3112867402core:ShareCapital2024-08-3112867402core:RetainedEarningsAccumulatedLosses2025-08-3112867402core:RetainedEarningsAccumulatedLosses2024-08-3112867402core:ShareCapitalOrdinaryShareClass12025-08-3112867402core:ShareCapitalOrdinaryShareClass12024-08-3112867402core:ShareCapitalOrdinaryShareClass22025-08-3112867402core:ShareCapitalOrdinaryShareClass22024-08-3112867402core:ShareCapitalOrdinaryShares2025-08-3112867402core:ShareCapitalOrdinaryShares2024-08-3112867402bus:Director12024-09-012025-08-31128674022023-09-012024-08-3112867402core:CurrentFinancialInstruments2024-08-3112867402core:CurrentFinancialInstrumentscore:WithinOneYear2024-09-012025-08-3112867402bus:OrdinaryShareClass12024-09-012025-08-3112867402bus:OrdinaryShareClass22024-09-012025-08-3112867402bus:OrdinaryShareClass12025-08-3112867402bus:OrdinaryShareClass12024-08-3112867402bus:OrdinaryShareClass22025-08-3112867402bus:OrdinaryShareClass22024-08-3112867402bus:AllOrdinaryShares2025-08-3112867402bus:AllOrdinaryShares2024-08-3112867402bus:PrivateLimitedCompanyLtd2024-09-012025-08-3112867402bus:SmallCompaniesRegimeForAccounts2024-09-012025-08-3112867402bus:FRS1022024-09-012025-08-3112867402bus:AuditExemptWithAccountantsReport2024-09-012025-08-3112867402bus:Director22024-09-012025-08-3112867402bus:FullAccounts2024-09-012025-08-31xbrli:purexbrli:sharesiso4217:GBP